Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5267323
Max Phase: Preclinical
Molecular Formula: C19H18Cl2N4O
Molecular Weight: 389.29
Associated Items:
ID: ALA5267323
Max Phase: Preclinical
Molecular Formula: C19H18Cl2N4O
Molecular Weight: 389.29
Associated Items:
Canonical SMILES: O=C(Cc1ccc(Cl)c(Cl)c1)N1CCN(c2ccc3cc[nH]c3n2)CC1
Standard InChI: InChI=1S/C19H18Cl2N4O/c20-15-3-1-13(11-16(15)21)12-18(26)25-9-7-24(8-10-25)17-4-2-14-5-6-22-19(14)23-17/h1-6,11H,7-10,12H2,(H,22,23)
Standard InChI Key: XZLKIRFFTJHQHG-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 389.29 | Molecular Weight (Monoisotopic): 388.0858 | AlogP: 3.76 | #Rotatable Bonds: 3 |
Polar Surface Area: 52.23 | Molecular Species: NEUTRAL | HBA: 3 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 5 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: 5.02 | CX LogP: 4.04 | CX LogD: 4.04 |
Aromatic Rings: 3 | Heavy Atoms: 26 | QED Weighted: 0.74 | Np Likeness Score: -1.53 |
1. Oboh E, Teixeira JE, Schubert TJ, Maribona AS, Denman BN, Patel R, Huston CD, Meyers MJ.. (2023) Structure-Activity relationships of replacements for the triazolopyridazine of Anti-Cryptosporidium lead SLU-2633., 86 [PMID:37148788] [10.1016/j.bmc.2023.117295] |
Source(1):